ClinicalTrials.gg
CompletedNCT01751165Updated Oct 18, 2018Results posted

Safety and Immunogenicity of Different Dosing Schedules of GlaxoSmithkline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine in Adults 50 Years of Age or Older

A Phase 3 interventional study of Herpes zoster vaccine GSK1437173A in Herpes Zoster, sponsored by GlaxoSmithKline. Completed at 4 sites in 2 countries. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-10-18.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
354
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies testing shingrix in Herpes Zoster — 8 open to participants now, 11 under way, 3 of them phase 3. shingrix · Herpes Zoster.

Enrollment
20th of 46
354 · median 239
Started
2013
with 3 others
Phase 3
22 of 46
2 open now
Registered
8th of 46
by date
Lead sponsor
26 of 46
GlaxoSmithKline

Among the 46 studies testing shingrix in Herpes Zoster, this one is the 20th largest by enrollment, is one of 4 that started in 2013, is one of 22 in phase 3, and was the 8th registered.

Herpes Zoster

299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

8 of the 46 studies testing shingrix in Herpes Zoster are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About shingrix

shingrix: first FDA approval 2017 (Shingrix). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing shingrix in Herpes Zoster, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and immunogenicity of the GSK Biologicals' HZ vaccine 1437173A administered on either a 0,2-; 0,6- or 0,12-month schedule in adults aged 50 years or above, as the immunogenicity of the HZ vaccine administered at intervals longer than two months is not known.

Read the detailed description

Subjects in each group will be stratified by age with a minimum of 35 subjects in each stratum (50-59 years of age (YOA) stratum, 60-69 YOA stratum and ≥ 70 YOA stratum).

03

Conditions studied

  • Herpes Zoster

Browse trials for

Keywords

  • ≥ 50 years of age
  • Herpes zoster
  • Safety
  • Immunogenicity
  • Adults
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
  • A male or female aged 50 years or older at the time of the first vaccination.
  • Written obtained from the subject.
  • Female subjects of non- may be enrolled in the study.

    • Non-childbearing potential is defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or .
  • Female subjects of childbearing potential may be enrolled in the study, if the subject:

    • has practiced adequate for 30 days prior to vaccination, and
    • has a negative pregnancy test on the day of vaccination, and
    • has agreed to continue adequate contraception during the entire treatment period and for two months after completion of the vaccination series.

Exclusion criteria

Exclusion Criteria:

  • Use of any or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.
  • Chronic administration of or other immune-modifying drugs within six months prior to the first vaccine dose. For , a prednisone dose of \< 20 mg/day, or equivalent, is allowed. Inhaled, topical and intra-articular corticosteroids are allowed.
  • Administration or planned administration of a in the period starting 30 days before and ending 30 days after either dose of study vaccine.
  • Administration or planned administration of a non-replicating vaccine within eight days prior to or within 14 days after either dose of study vaccine.
  • Administration of long-acting immune-modifying drugs (e.g. infliximab) within six months prior to the first vaccine dose or expected administration at any time during the study period.
  • Previous vaccination against varicella or HZ (either registered product or participation in a previous vaccine study).
  • Planned administration during the study of an HZ or varicella vaccine (including an investigational or non-registered vaccine) other than the study vaccine.
  • History of HZ.
  • History of any reaction or likely to be exacerbated by any component of the vaccine(s).
  • Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease (e.g. , [HIV] infection) or immunosuppressive/cytotoxic therapy (e.g. medications used during cancer chemotherapy, organ transplantation or to treat disorders).
  • Acute disease and/or fever at the time of enrolment.

    • Fever is defined as temperature ≥ 37.5°C (99.5°F) for oral, axillary or tympanic route, or ≥ 38.0°C (100.4°F) for rectal route. The preferred route for recording temperature in this study will be oral.
    • Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory infection) without fever may be enrolled at the discretion of the investigator.
  • Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.
  • Significant underlying illness that, in the opinion of the investigator, would be expected to prevent completion of the study.
  • Any other condition that, in the opinion of the investigator, might interfere with the evaluations required by the study.
  • Pregnant or lactating female.
  • Female planning to become pregnant during the entire treatment period and for two months after completion of the vaccination series, or planning to discontinue precautions (if of ).
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
354 participants (actual)

Study arms

  • Experimental
    HZ/su-0,2 Group

    Subjects will receive HZ/su vaccine on a 0,2-month schedule.

    Biological: Herpes zoster vaccine GSK1437173A

  • Experimental
    HZ/su-0,6 Group

    Subjects will receive HZ/su vaccine on a 0,6-month schedule.

    Biological: Herpes zoster vaccine GSK1437173A

  • Experimental
    HZ/su-0,12 Group

    Subjects will receive HZ/su vaccine on a 0,12-month schedule.

    Biological: Herpes zoster vaccine GSK1437173A

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Vaccine Response to Anti-glycoprotein E (Anti-gE) Antibodies as Determined by the Enzyme-linked Immunosorbent Assay (ELISA).

    Vaccine response was defined as: for initially seronegative subjects, antibody concentration at post-vaccination ≥ 4 fold the cut-off for Anti-gE (4x97 mIU/mL); for initially seropositive subjects, antibody concentration at post-vaccination ≥ 4 fold the pre-vaccination antibody concentration. The objective required a comparison of VRR between 0,6-months and 0,12-months schedules.

    Time frame: At one month (M1) after Dose 2

  2. Concentrations of Antibodies Against Anti-gE as Determined by ELISA.

    Time frame: At one month (M1) after Dose 2

Secondary outcomes

  1. Concentrations of Antibodies Against Anti-gE as Determined by ELISA.

    Time frame: Prior (PRE) to vaccination and twelve (M12) post Dose 2

  2. Number of Subjects With Solicited Local Symptoms.

    Solicited local symptoms assessed include pain, redness and swelling. "Grade 3 pain" was defined as crying when limb was moved/spontaneously painful. "Grade 3 swelling/redness" was defined as swelling/redness larger than (\>) 100 millimeters (mm). "Any" is defined as incidence of the specified symptom regardless of intensity.

    Time frame: During the 7 day period (Days 0-6) following each dose (D)

  3. Number of Subjects With Solicited General Symptoms.

    Assessed solicited general symptoms were Fatigue, Gastrointestinal (meaning nausea, vomiting, diarrhoea and/or abdominal pain), Headache, Myalgia, Shivering and Temperature (temperature higher than \[≥\] 37.5 degrees Celsius \[°C\]). "Any" = occurrence of the specified solicited general symptom, regardless of intensity or relationship to vaccination. "Related" = occurrence of the specified symptom assessed by the investigators as causally related to vaccination. "Grade 3 Fatigue" = fatigue that prevented normal activity. "Grade 3 Gastrointestinal" = gastrointestinal that prevented normal every day activities. "Grade 3 Headache" = headache that prevented normal activity. "Grade 3 Myalgia" = myalgia that prevented normal activity. "Grade 3 Shivering" = shivering that prevented normal activity. "Grade 3 Temperature" = temperature higher than (\>) 39.0°C.

    Time frame: During the 7 day period (Days 0-6) following each dose (D)

  4. Number of Subjects With Unsolicited Adverse Events (AEs).

    An adverse event (AE) is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

    Time frame: During the 30 Days (Day 0-29) following vaccination

  5. Number of Subjects With Serious Adverse Events (SAEs).

    SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity.

    Time frame: From first vaccination up to one month (30 Days) post last vaccination

  6. Number of Subjects With SAE(s).

    SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity.

    Time frame: Starting from 30 Days post last vaccine administration up to study end at Month 24

  7. Number of Days With Solicited Local Symptoms.

    Each dose was abbreviated as follows: D1 = Dose 1, D2 = Dose 2.

    Time frame: During the 7 Days (Day 0-6) following vaccination

  8. Number of Days With Solicited General Symptoms.

    Each dose was abbreviated as follows: D1 = Dose 1, D2 = Dose 2.

    Time frame: During the 7 Days (Day 0-6) following vaccination

  9. Number of Subjects With Potential Immune-mediated Diseases (pIMDs).

    pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.

    Time frame: From Dose 1 up to one month (30 days) following the last vaccine dose administration (Dose 2)

  10. Number of Subjects With pIMDs.

    pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.

    Time frame: From one month (30 Days) following the last vaccine administration up to study end at Month 24

07

Results

Posted Mar 31, 2017

Participant flow

Participant flow — Overall Study
MilestoneGSK1437173A-0,2 M GroupGSK1437173A-0,6 M GroupGSK1437173A-0,12 M Group
Started119119116
Completed117116113
Not completed233
Withdrew: Adverse event, serious fatal101
Withdrew: Withdrawal by subject001
Withdrew: Serious adverse event020
Withdrew: Lost to follow-up111

Outcome measures

PrimaryNumber of Subjects With Vaccine Response to Anti-glycoprotein E (Anti-gE) Antibodies as Determined by the Enzyme-linked Immunosorbent Assay (ELISA).

Vaccine response was defined as: for initially seronegative subjects, antibody concentration at post-vaccination ≥ 4 fold the cut-off for Anti-gE (4x97 mIU/mL); for initially seropositive subjects, antibody concentration at post-vaccination ≥ 4 fold the pre-vaccination antibody concentration. The objective required a comparison of VRR between 0,6-months and 0,12-months schedules.

Time frame:
At one month (M1) after Dose 2
Reported as:
Number · Subjects
Number of Subjects With Vaccine Response to Anti-glycoprotein E (Anti-gE) Antibodies as Determined by the Enzyme-linked Immunosorbent Assay (ELISA).
SubjectsGSK1437173A-0,6 M GroupGSK1437173A-0,12 M Group
Number of Subjects With Vaccine Response to Anti-glycoprotein E (Anti-gE) Antibodies as Determined by the Enzyme-linked Immunosorbent Assay (ELISA).110104
PrimaryConcentrations of Antibodies Against Anti-gE as Determined by ELISA.
Time frame:
At one month (M1) after Dose 2
Reported as:
Geometric mean · mIU/mL
Concentrations of Antibodies Against Anti-gE as Determined by ELISA.
mIU/mLGSK1437173A-0,2 M GroupGSK1437173A-0,6 M GroupGSK1437173A-0,12 M Group
Concentrations of Antibodies Against Anti-gE as Determined by ELISA.44376.3 (39697 to 49607.2)38153.7 (34205.8 to 42557.3)37435.8 (30813.8 to 45480.8)
Statistical analysis
  • GSK1437173A-0,2 M Group vs GSK1437173A-0,6 M Group · ANCOVA · Adjusted gmc ratio: 1.16 · 97.5% CI 0.98 to 1.39
  • GSK1437173A-0,2 M Group vs GSK1437173A-0,12 M Group · ANCOVA · Adjusted gmc ratio: 1.19 · 97.5% CI 0.93 to 1.53
SecondaryConcentrations of Antibodies Against Anti-gE as Determined by ELISA.
Time frame:
Prior (PRE) to vaccination and twelve (M12) post Dose 2
Reported as:
Geometric mean · mIU/mL
Concentrations of Antibodies Against Anti-gE as Determined by ELISA.
mIU/mLGSK1437173A-0,2 M GroupGSK1437173A-0,6 M GroupGSK1437173A-0,12 M Group
Anti-gE, PRE [N=118,114,110]1079.1 (891.9 to 1305.5)1066.1 (891.3 to 1275.3)1019.4 (858.6 to 1210.2)
Anti-gE, M12 [N=117,115,110]14245.4 (12450.8 to 16298.6)12911.5 (11412.7 to 14607.2)11892.1 (10236.4 to 13815.6)
SecondaryNumber of Subjects With Solicited Local Symptoms.

Solicited local symptoms assessed include pain, redness and swelling. "Grade 3 pain" was defined as crying when limb was moved/spontaneously painful. "Grade 3 swelling/redness" was defined as swelling/redness larger than (\>) 100 millimeters (mm). "Any" is defined as incidence of the specified symptom regardless of intensity.

Time frame:
During the 7 day period (Days 0-6) following each dose (D)
Reported as:
Number · Subjects
Number of Subjects With Solicited Local Symptoms.
SubjectsGSK1437173A-0,2 M GroupGSK1437173A-0,6 M GroupGSK1437173A-0,12 M Group
Any Pain, D1 [N=119,119,115]847780
Grade 3 Pain, D1 [N=119,119,115]102
Any Redness, D1 [N=119,119,115]373932
Grade 3 Redness, D1 [N=119,119,115]001
Any Swelling, D1 [N=119,119,115]172325
Grade 3 Swelling, D1 [N=119,119,115]000
Any Pain, D2 [N=118,117,111]718387
Grade 3 Pain, D2 [N=118,117,111]6610
Any Redness, D2 [N=118,117,111]282737
Grade 3 Redness, D2 [N=118,117,111]200
Any Swelling, D2 [N=118,117,111]15924
Grade 3 Swelling, D2 [N=118,117,111]000
Any Pain, Across [N=119,119,116]919598
Grade 3 Pain, Across [N=119,119,116]7612
Any Redness, Across [N=119,119,116]485053
Grade 3 Redness, Across [N=119,119,116]201
Any Swelling, Across [N=119,119,116]262839
Grade 3 Swelling, Across [N=119,119,116]000
SecondaryNumber of Subjects With Solicited General Symptoms.

Assessed solicited general symptoms were Fatigue, Gastrointestinal (meaning nausea, vomiting, diarrhoea and/or abdominal pain), Headache, Myalgia, Shivering and Temperature (temperature higher than \[≥\] 37.5 degrees Celsius \[°C\]). "Any" = occurrence of the specified solicited general symptom, regardless of intensity or relationship to vaccination. "Related" = occurrence of the specified symptom assessed by the investigators as causally related to vaccination. "Grade 3 Fatigue" = fatigue that prevented normal activity. "Grade 3 Gastrointestinal" = gastrointestinal that prevented normal every day activities. "Grade 3 Headache" = headache that prevented normal activity. "Grade 3 Myalgia" = myalgia that prevented normal activity. "Grade 3 Shivering" = shivering that prevented normal activity. "Grade 3 Temperature" = temperature higher than (\>) 39.0°C.

Time frame:
During the 7 day period (Days 0-6) following each dose (D)
Reported as:
Number · Subjects
Number of Subjects With Solicited General Symptoms.
SubjectsGSK1437173A-0,2 M GroupGSK1437173A-0,6 M GroupGSK1437173A-0,12 M Group
Any Fatigue, D1 [N=119,119,115]425046
Grade 3 Fatigue, D1 [N=119,119,115]310
Related Fatigue, D1 [N=119,119,115]374938
Any Gastrointestinal, D1 [N=119,119,115]221717
Grade 3 Gastrointestinal, D1 [N=119,119,115]310
Related Gastrointestinal, D1 [N=119,119,115]191412
Any Headache, D1 [N=119,119,115]353934
Grade 3 Headache, D1 [N=119,119,115]110
Related Headache, D1 [N=119,119,115]313126
Any Myalgia, D1 [N=119,119,115]433846
Grade 3 Myalgia, D1 [N=119,119,115]220
Related Myalgia, D1 [N=119,119,115]363340
Any Shivering, D1 [N=119,119,115]252529
Grade 3 Shivering, D1 [N=119,119,115]100
Related Shivering, D1 [N=119,119,115]222226
Any Temperature, D1 [N=119,119,115]212214
Grade 3 Temperature, D1 [N=119,119,115]100
Related Temperature, D1 [N=119,119,115]192113
Any Fatigue, D2 [N=118,117,111]434659
Grade 3 Fatigue, D2 [N=118,117,111]444
Related Fatigue, D2 [N=118,117,111]414156
Any Gastrointestinal, D2 [N=118,117,111]14512
Grade 3 Gastrointestinal, D2 [N=118,117,111]011
Related Gastrointestinal, D2 [N=118,117,111]14510
Any Headache, D2 [N=118,117,111]362737
Grade 3 Headache, D2 [N=118,117,111]235
Related Headache, D2 [N=118,117,111]322233
Any Myalgia, D2 [N=118,117,111]484243
Grade 3 Myalgia, D2 [N=118,117,111]523
Related Myalgia, D2 [N=118,117,111]463938
Any Shivering, D2 [N=118,117,111]252335
Grade 3 Shivering, D2 [N=118,117,111]333
Related Shivering, D2 [N=118,117,111]242031
Any Temperature, D2 [N=118,117,111]201626
Grade 3 Temperature, D2 [N=118,117,111]002
Related Temperature, D2 [N=118,117,111]191624
Any Fatigue, Across [N=119,119,116]546371
Grade 3 Fatigue, Across [N=119,119,116]754
Related Fatigue, Across [N=119,119,116]495765
Any Gastrointestinal, Across [N=119,119,116]272027
Grade 3 Gastrointestinal, Across [N=119,119,116]321
Related Gastrointestinal, Across [N=119,119,116]261721
Any Headache, Across [N=119,119,116]474753
Grade 3 Headache, Across [N=119,119,116]245
Related Headache, Across [N=119,119,116]413845
Any Myalgia, Across [N=119,119,116]635764
Grade 3 Myalgia, Across [N=119,119,116]743
Related Myalgia, Across [N=119,119,116]575257
Any Shivering, Across [N=119,119,116]373548
Grade 3 Shivering, Across [N=119,119,116]433
Related Shivering, Across [N=119,119,116]342943
Any Temperature, Across [N=119,119,116]323233
Grade 3 Temperature, Across [N=119,119,116]102
Related Temperature, Across [N=119,119,116]293130
SecondaryNumber of Subjects With Unsolicited Adverse Events (AEs).

An adverse event (AE) is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Time frame:
During the 30 Days (Day 0-29) following vaccination
Reported as:
Number · Subjects
Number of Subjects With Unsolicited Adverse Events (AEs).
SubjectsGSK1437173A-0,2 M GroupGSK1437173A-0,6 M GroupGSK1437173A-0,12 M Group
Any AEs272723
Grade 3 AEs444
Related AEs957
SecondaryNumber of Subjects With Serious Adverse Events (SAEs).

SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity.

Time frame:
From first vaccination up to one month (30 Days) post last vaccination
Reported as:
Number · Subjects
Number of Subjects With Serious Adverse Events (SAEs).
SubjectsGSK1437173A-0,2 M GroupGSK1437173A-0,6 M GroupGSK1437173A-0,12 M Group
Number of Subjects With Serious Adverse Events (SAEs).048
SecondaryNumber of Subjects With SAE(s).

SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity.

Time frame:
Starting from 30 Days post last vaccine administration up to study end at Month 24
Reported as:
Number · Subjects
Number of Subjects With SAE(s).
SubjectsGSK1437173A-0,2 M GroupGSK1437173A-0,6 M GroupGSK1437173A-0,12 M Group
Number of Subjects With SAE(s).564
SecondaryNumber of Days With Solicited Local Symptoms.

Each dose was abbreviated as follows: D1 = Dose 1, D2 = Dose 2.

Time frame:
During the 7 Days (Day 0-6) following vaccination
Reported as:
Number · Days
Number of Days With Solicited Local Symptoms.
DaysGSK1437173A-0,2 M GroupGSK1437173A-0,6 M GroupGSK1437173A-0,12 M Group
Days with Pain, D1847780
Days with Pain, D2718387
Days with Redness, D1373932
Days with Redness, D2282737
Days with Swelling, D1172325
Days with Swelling, D215924
SecondaryNumber of Days With Solicited General Symptoms.

Each dose was abbreviated as follows: D1 = Dose 1, D2 = Dose 2.

Time frame:
During the 7 Days (Day 0-6) following vaccination
Reported as:
Number · Days
Number of Days With Solicited General Symptoms.
DaysGSK1437173A-0,2 M GroupGSK1437173A-0,6 M GroupGSK1437173A-0,12 M Group
Days with Fatigue, D1425046
Days with Fatigue, D2434659
Days with Gastrointestinal, D1221717
Days with Gastrointestinal, D214512
Days with Headache, D1353934
Days with Headache, D2362737
Days with Myalgia, D1433846
Days with Myalgia, D2484243
Days with Shivering, D1252529
Days with Shivering, D2252335
Days with Temperature, D1212214
Days with Temperature, D2201626
SecondaryNumber of Subjects With Potential Immune-mediated Diseases (pIMDs).

pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.

Time frame:
From Dose 1 up to one month (30 days) following the last vaccine dose administration (Dose 2)
Reported as:
Number · Subjects
Number of Subjects With Potential Immune-mediated Diseases (pIMDs).
SubjectsGSK1437173A-0,2 M GroupGSK1437173A-0,6 M GroupGSK1437173A-0,12 M Group
Number of Subjects With Potential Immune-mediated Diseases (pIMDs).000
SecondaryNumber of Subjects With pIMDs.

pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.

Time frame:
From one month (30 Days) following the last vaccine administration up to study end at Month 24
Reported as:
Number · Subjects
Number of Subjects With pIMDs.
SubjectsGSK1437173A-0,2 M GroupGSK1437173A-0,6 M GroupGSK1437173A-0,12 M Group
Number of Subjects With pIMDs.000

Adverse events

Collected over Serious Adverse Events were collected during the entire study period (up to Month 24). Other Adverse Events were collected during the 30 Day post-vaccination period (Day 0 - Day 29).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GSK1437173A-0,2 M Group—5/119 (4.2%)107/119 (89.9%)
GSK1437173A-0,6 M Group—9/119 (7.6%)106/119 (89.1%)
GSK1437173A-0,12 M Group—12/116 (10.3%)107/116 (92.2%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventGSK1437173A-0,2 M GroupGSK1437173A-0,6 M GroupGSK1437173A-0,12 M Group
Cerebral infarctionNervous system disorders0/1192/1190/116
AnaemiaBlood and lymphatic system disorders0/1190/1191/116
Cardiovascular disorderCardiac disorders0/1190/1191/116
DiverticulumGastrointestinal disorders1/1190/1191/116
Inguinal herniaGastrointestinal disorders0/1190/1191/116
Mallory-weiss syndromeGastrointestinal disorders0/1190/1191/116
Varices oesophagealGastrointestinal disorders0/1190/1191/116
Helicobacter gastritisInfections and infestations0/1190/1191/116
InjuryInjury, poisoning and procedural complications0/1190/1191/116
DyslipidaemiaMetabolism and nutrition disorders0/1190/1191/116
Most frequent other events
Most frequent other events
EventGSK1437173A-0,2 M GroupGSK1437173A-0,6 M GroupGSK1437173A-0,12 M Group
PainGeneral disorders91/11995/11998/116
FatigueGeneral disorders54/11963/11971/116
MyalgiaMusculoskeletal and connective tissue disorders63/11957/11964/116
ErythemaSkin and subcutaneous tissue disorders48/11951/11953/116
HeadacheNervous system disorders48/11948/11953/116
ChillsGeneral disorders37/11935/11948/116
SwellingGeneral disorders26/11928/11939/116
PyrexiaGeneral disorders32/11932/11933/116
Gastrointestinal disorderGastrointestinal disorders27/11920/11927/116

Baseline characteristics

Age, Continuous
Age, Continuous(Years)GSK1437173A-0,2 M GroupGSK1437173A-0,6 M GroupGSK1437173A-0,12 M GroupTotal
Mean64.5 ± 8.964 ± 8.664.1 ± 9.264.2 ± 8.88
Sex: Female, Male
Sex: Female, Male(Participants)GSK1437173A-0,2 M GroupGSK1437173A-0,6 M GroupGSK1437173A-0,12 M GroupTotal
Female907779246
Male294237108
08

Study locations

4 sites
  • GSK Investigational Site
    Spring Valley, California 91978, United States
  • GSK Investigational Site
    Wichita, Kansas 67207, United States
  • GSK Investigational Site
    Uniontown, Pennsylvania 15401, United States
  • GSK Investigational Site
    Tartu, 50106, Estonia
09

References and documents

Publications

  • Lal H, Poder A, Campora L, Geeraerts B, Oostvogels L, Vanden Abeele C, Heineman TC. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: Results of a phase III, randomized, open-label, multicenter study. Vaccine. 2018 Jan 2;36(1):148-154. doi: 10.1016/j.vaccine.2017.11.019. Epub 2017 Nov 22. PubMed 29174683 ↗

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2013, a primary completion of May 2014 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2017, 2 years 10 months after primary completion. A results delay was requested in Mar 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2012
First posted
Dec 17, 2012
Start
Mar 12, 2013
Primary completionActual
May 22, 2014
CompletionActual
Apr 8, 2015
Results delay requested
Mar 12, 2015
Results first posted
Mar 31, 2017
Last update
Oct 18, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 18, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01751165
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Dec 17, 2012
Start date
Mar 12, 2013
Primary completion
May 22, 2014
Completion
Apr 8, 2015
Results posted
Mar 31, 2017
Last update
Oct 18, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Shingrix

Start the discussion